We have previously described the production and anti-cancer activity of a dual-cytokine fusion protein (termed IL2-F8-TNFmut), which exhibited a selective accumulation at the tumor site following intravenous administration and a potent anti-cancer activity, particularly against murine soft-tissue sarcomas (6). The gene discussed is IL2; the disease is cancer.